The ruling means that small-scale compounders must immediately stop making their versions of Novo’s Ozempic and Wegovy, while ...

AstraZeneca and Daiichi Sankyo are gunning to get Enhertu a new first-line approval in HER2-positive breast cancer after a ...

Merck KGaA’s protracted pursuit of SpringWorks Therapeutics may be nearing its endgame. | Merck KGaA’s protracted pursuit of ...

With the threat of Trump administration's tariffs swirling and biopharma companies bracing for impact, many are announcing ...

Halozyme is not holding back against Merck & Co. in the companies' injectable Keytruda patent dispute, having now escalated a ...

We’ve known for a while that there are two Anguses—both journalists covering oncology at health- and biopharma-focused news outlets. | Two journalists, one name and a candid conversation—Angus Liu and ...

Like several other biopharmas before it, UCB has turned to perhaps the most recognizable dermatologist in the U.S. to add ...

On the heels of a clinical setback for Bristol Myers Squibb’s schizophrenia newcomer Cobenfy, the New Jersey pharma is ...

With potential tariffs and other drug pricing policies on the horizon, the industry is navigating uncertain waters. | The ...

Pharmacy benefit managers (PBMs) are up to bat in the perpetual blame game between PBMs and the pharmaceutical industry. | ...

While much of the conversation around the Trump administration’s potential pharmaceutical import tariffs has leaned heavily ...

As Sanofi anticipates sales of immunotherapy juggernaut Dupixent reaching a major $22 billion by the end of the decade, ...